Literature DB >> 3045341

Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.

M Waldhauser1, P Schramek.   

Abstract

The efficiency and side effects of a single dose of intracorporeally applied prostaglandin E1 (20 mcg.) in inducing penile erection were examined. In addition, the effect of this dose of prostaglandin E1 was compared to the effect of 7.5 mg. papaverine plus 0.25 mg. phentolamine in a double-blind, crossover designed study. We tested twice 12 men 52.9 +/- 7.6 years old (mean +/- standard deviation) with erectile dysfunction. On 1 occasion the subjects received 20 mcg. prostaglandin E1 and on the other they received 7.5 mg. papaverine and 0.25 mg. phentolamine. At this dosage prostaglandin E1 was most effective in inducing artificial penile erection (11 of 12 patients). However, 75 per cent of the subjects reported burning sensations during the entire period of erection and in 1 prostaglandin E1 treatment resulted in a sustained erection. At the doses used, prostaglandin E1 was more effective in inducing penile erection than papaverine plus phentolamine (11 versus 6 patients). Intracavernous injection of prostaglandin E1 is a potent tool for artificial penile erection and warrants precise examination for its potential clinical use.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3045341     DOI: 10.1016/s0022-5347(17)41709-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Comparison of Alprostadil (Caverject) and a combination of vasoactive drugs as local injections for the treatment of erectile dysfunction.

Authors:  H M Abdallah
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 2.  New developments in the diagnosis and treatment of impotence.

Authors:  R G De Palma
Journal:  West J Med       Date:  1996-01

3.  Colour penile Doppler ultrasonography with intraurethral prostaglandin-E2: preliminary results.

Authors:  M Başar; H Başar; L Aydoğanli; K Alkan; O Gümüş; Z Akalin
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 4.  Intracavernous pharmacotherapy.

Authors:  M C Truss; A J Becker; D Schultheiss; U Jonas
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

Review 6.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

7.  Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction.

Authors:  P Schramek; M Waldhauser
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

8.  Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic.

Authors:  D K Armstrong; A Convery; W W Dinsmore
Journal:  Ulster Med J       Date:  1994-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.